Literature DB >> 32333965

Dichotomy of complement system: Tumorigenesis or destruction.

Ashima Sinha1, Virendra Singh2, Ravi Tandon3, Lalit Mohan Srivastava4.   

Abstract

Complement system proteins, their regulators and endpoint effector complex significantly promote tumor growth by upregulation of oncogenic growth factors, activation of mitogenic signalling pathways and breakage of normal cell cycle. Contrastingly, complement cascades, initiated by anti-tumor therapeutic antibodies, also play a pivotal role in therapy response. This contradictory role of complement system possibly be a very crucial factor for the outcomes of antibody mediated immunotherapies. Herein, we reviewed the twin role of the complement system in cancer and also the genetic variations in complement system genes. Future studies should be focused on the biomarker discovery for the personalised cancer immunotherapies.
Copyright © 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cancer immunotherapies; Complement system; Tumor immunology

Mesh:

Substances:

Year:  2020        PMID: 32333965     DOI: 10.1016/j.imlet.2020.04.013

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

1.  The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases.

Authors:  Wen Q Qiu; Shaopeiwen Luo; Stefanie A Ma; Priyanka Saminathan; Herman Li; Jenny M Gunnersen; Harris A Gelbard; Jennetta W Hammond
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

Review 2.  Components of the Lectin Pathway of Complement in Solid Tumour Cancers.

Authors:  Maciej Cedzyński; Anna S Świerzko
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.